Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis

Arthritis and Rheumatism

Volumn 60, Issue 5, 2009, Pages 1519-1529

  Hemmatazad, Hossein ^a   Rodrigues, Hanna Maciejewska ^a   Maurer, Britta ^a   Brentano, Fabia ^a   Pileckyte, Margarita ^b   Distler, Jörg H W ^a,c   Gay, Renate E ^a   Michel, Beat A ^a   Gay, Steffen ^a   Huber, Lars C ^a   Distler, Oliver ^a   Jüngel, Astrid ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b KAUNAS UNIVERSITY OF MEDICINE HOSPITAL   (Lithuania)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SCLEROPROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELLS, CULTURED; COLLAGEN TYPE I; COLLAGEN TYPE III; CONNECTIVE TISSUE GROWTH FACTOR; ENZYME INHIBITORS; EXTRACELLULAR MATRIX PROTEINS; FIBROBLASTS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INTERCELLULAR ADHESION MOLECULE-1; POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 66049096156     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24494     Document Type: Article

References (41)

1. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005;45:495-528. (Pubitemid 40261815)
2. Chung YL, Lee MY, Wang AJ, Yao LF. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003;8:707-717 (Pubitemid 37527445)
3. Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006;54:2271-2279 (Pubitemid 44051084)
4. Ghosh AK, Varga J. The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J Cell Physiol 2007;213:663-671 (Pubitemid 350058260)
5. Ghosh AK, Mori Y, Dowling E, Varga J. Trichostatin A blocks TGF-β-induced collagen gene expression in skin fibroblasts: involvement of Sp1. Biochem Biophys Res Commun 2007;354:420-426 (Pubitemid 46161342)
6. Huber LC, Distler JH, Moritz F, Hemmatazad H, Hauser T, Michel BA, et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum 2007;56:2755-2764
7. Walkinshaw DR, Yang XJ. Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 2008;15:237-243
8. Huang L. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J Cell Physiol 2006;209:611-616 (Pubitemid 44665677)
9. Ellmers LJ, Scott NJ, Piuhola J, Maeda N, Smithies O, Frampton CM, et al. Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol Endocrinol 2007;38:245-257
10. Dokmanovic M, Marks PA. Histone deacetylase inhibitors. J Cell Biochem 2005;96:293-304.
11. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265:17174-17179 (Pubitemid 20334262)
12. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409:581-589
13. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-205
14. 2 via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. Arthritis Rheum 2007;56:3564-3574
15. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367:1683-1691
16. Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 2008;47 Suppl 5:v2-4.
17. Mottet D, Bellahcene A, Pirotte S, Waltregny D, Deroanne C, Lamour V, et al. Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ Res 2007;101:1237-1246
18. Ihn H. Autocrine TGF-β signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 2008;49:103-113
19. Matsushita Y, Hasegawa M, Matsushita T, Fujimoto M, Horikawa M, Fujita T, et al. Intercellular adhesion molecule-1 deficiency attenuates the development of skin fibrosis in tight-skin mice. J Immunol 2007;179:698-707.
20. Vanhaecke T, Papeleu P, Elaut G, Rogiers V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem 2004;11:1629-1643 (Pubitemid 38735799)
21. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996;5:245-253 (Pubitemid 126682821)
22. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005;102:3697-3702
23. Papeleu P, Vanhaecke T, Elaut G, Vinken M, Henkens T, Snykers S, et al. Differential effects of histone deacetylase inhibitors in tumor and normal cells - what is the toxicological relevance? Crit Rev Toxicol 2005;35:363-378
24. Elaut G, Torok G, Vinken M, Laus G, Papeleu P, Tourwe D, et al. Major phase I biotransformation pathways of trichostatin A in rat hepatocytes and in rat and human liver microsomes. Drug Metab Dispos 2002;30:1320-1328
25. Charrier C, Bertrand P, Gesson JP, Roche J. Synthesis of rigid trichostatin A analogs as HDAC inhibitors. Bioorg Med Chem Lett 2006;16:5339-5344 (Pubitemid 44332216)
26. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 2001;7:971-976
27. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002;62:4916-4921
28. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003;100:4389-4394 (Pubitemid 36457739)
29. Yang XJ, Gregoire S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol 2005;25:2873-2884 (Pubitemid 40464294)
30. Xiao R, Liu FY, Luo JY, Yang XJ, Wen HQ, Su YW, et al. Effect of small interfering RNA on the expression of connective tissue growth factor and type I and III collagen in skin fibroblasts of patients with systemic sclerosis. Br J Dermatol 2006;155:1145-1153
31. Denton CP, Abraham DJ. Transforming growth factor-β and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001;13:505-511 (Pubitemid 33070969)
32. Leask A. Transcriptional profiling of the scleroderma fibroblast reveals a potential role for connective tissue growth factor (CTGF) in pathological fibrosis. Keio J Med 2004;53:74-77 (Pubitemid 38899739)
33. Dokmanovic M, Perez G, Xu W, Ngo L, Clarke C, Parmigiani RB, et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther 2007;6:2525-2534
34. Kasler HG, Verdin E. Histone deacetylase 7 functions as a key regulator of genes involved in both positive and negative selection of thymocytes. Mol Cell Biol 2007;27:5184-5200 (Pubitemid 47068292)
35. Dequiedt F, Kasler H, Fischle W, Kiermer V, Weinstein M, Herndier BG, et al. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 2003;18:687-698
36. Dressel U, Bailey PJ, Wang SC, Downes M, Evans RM, Muscat GE. A dynamic role for HDAC7 in MEF2-mediated muscle differentiation. J Biol Chem 2001;276:17007-17013 (Pubitemid 37411499)
37. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007;5:981-989 (Pubitemid 350080267)
38. Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006;126:321-334 (Pubitemid 44092958)
39. Kato H, Tamamizu-Kato S, Shibasaki F. Histone deacetylase 7 associates with hypoxia-inducible factor 1α and increases transcriptional activity. J Biol Chem 2004;279:41966-41974 (Pubitemid 39313647)
40. Kao HY, Downes M, Ordentlich P, Evans RM. Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev 2000;14:55-66. (Pubitemid 30051579)
41. Fischle W, Dequiedt F, Fillion M, Hendzel MJ, Voelter W, Verdin E. Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem 2001;276:35826-35835 (Pubitemid 37384388)